# Catalent Inc. (CTLT)

Source: https://www.quantisnow.com/company/CTLT
Generated: 2026-11-09T23:16:35.969Z

- Ticker: CTLT
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: catalent.com

## About

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

## Latest CTLT news and filings

- 2025-02-20 14:00 UTC [Leadership Update] [Catalent Announces New Board Appointments](https://www.quantisnow.com/insight/catalent-announces-new-board-appointments-5899386)
- 2024-12-30 13:00 UTC [SEC Form 15-12G filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-catalent-inc-5826518)
- 2024-12-18 22:46 UTC [Leadership Update] [Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400](https://www.quantisnow.com/insight/lennox-international-set-to-join-sp-500-and-bill-holdings-5819291)
- 2024-12-18 19:10 UTC [SEC Form 4] [Group Pres. Pharma & Consumer Gennadios Aristippos returned 135,286 shares to the company and was granted 21,562 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/group-pres-pharma-consumer-gennadios-aristippos-returned-135286-shares-to-5818548)
- 2024-12-18 19:07 UTC [SEC Form 4] [Group President, Biologics Mcerlane David returned 47,730 shares to the company and was granted 11,426 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/group-president-biologics-mcerlane-david-returned-47730-shares-to-the-5818547)
- 2024-12-18 19:05 UTC [SEC Form 4] [Chief Accounting Officer Hatzfeld Michael returned 16,676 shares to the company and was granted 3,144 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-accounting-officer-hatzfeld-michael-returned-16676-shares-to-the-5818545)
- 2024-12-18 19:00 UTC [SEC Form 4] [SVP, Quality & Reg. Affairs Gunther Scott returned 52,573 shares to the company and was granted 12,938 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/svp-quality-reg-affairs-gunther-scott-returned-52573-shares-to-5818544)
- 2024-12-18 18:56 UTC [SEC Form 4] [SVP, General Counsel, CCO Ferraro Joseph Anthony was granted 14,265 shares and returned 38,232 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/svp-general-counsel-cco-ferraro-joseph-anthony-was-granted-14265-5818541)
- 2024-12-18 18:20 UTC [SEC Form 4] [Director Stahl Jack L returned 47,984 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-stahl-jack-l-returned-47984-shares-to-the-company-5818520)
- 2024-12-18 18:18 UTC [SEC Form 4] [Director Ryan Michelle R returned 10,835 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ryan-michelle-r-returned-10835-shares-to-the-company-5818519)
- 2024-12-18 18:08 UTC [SEC Form 4] [Director Okey Stephanie returned 12,635 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-okey-stephanie-returned-12635-shares-to-the-company-closing-5818511)
- 2024-12-18 18:06 UTC [SEC Form 4] [Director Morel Donald E Jr returned 70,118 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-morel-donald-e-jr-returned-70118-shares-to-the-5818506)
- 2024-12-18 18:04 UTC [SEC Form 4] [Director Lucier Gregory T returned 36,914 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-lucier-gregory-t-returned-36914-shares-to-the-company-5818504)
- 2024-12-18 18:01 UTC [SEC Form 4] [Director Damelio Frank A returned 12,635 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-damelio-frank-a-returned-12635-shares-to-the-company-5818501)
- 2024-12-18 17:59 UTC [SEC Form 4] [Director Classon Rolf A returned 47,984 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-classon-rolf-a-returned-47984-shares-to-the-company-5818500)
- 2024-12-18 17:57 UTC [SEC Form 4] [Director Carroll J Martin returned 32,734 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-carroll-j-martin-returned-32734-shares-to-the-company-5818498)
- 2024-12-18 17:55 UTC [SEC Form 4] [Director Barg Steven returned 12,374 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-barg-steven-returned-12374-shares-to-the-company-closing-5818497)
- 2024-12-18 17:52 UTC [SEC Form 4] [Director Barber Michael J returned 18,052 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-barber-michael-j-returned-18052-shares-to-the-company-5818494)
- 2024-12-18 16:13 UTC [SEC Form 4] [President & CEO Maselli Alessandro returned 290,745 shares to the company and was granted 113,224 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-maselli-alessandro-returned-290745-shares-to-the-company-5818427)
- 2024-12-18 16:12 UTC [SEC Form 4] [Pres. BioProduct Delivery, CoS Hopson Ricky returned 40,696 shares to the company and was granted 10,722 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/pres-bioproduct-delivery-cos-hopson-ricky-returned-40696-shares-to-5818426)
- 2024-12-18 16:12 UTC [SEC Form 4] [Executive Chair Greisch John J returned 147,462 shares to the company and was granted 33,530 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/executive-chair-greisch-john-j-returned-147462-shares-to-the-5818424)
- 2024-12-18 16:12 UTC [SEC Form 4] [SVP, Chief Financial Officer Masanovich Matti returned 148,166 shares to the company and was granted 71,691 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/svp-chief-financial-officer-masanovich-matti-returned-148166-shares-to-5818423)
- 2024-12-18 16:11 UTC [SEC Form 4] [SVP, Chief HR Officer Evoli Lisa returned 51,398 shares to the company and was granted 12,032 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/svp-chief-hr-officer-evoli-lisa-returned-51398-shares-to-5818422)
- 2024-12-18 15:38 UTC [SEC Form POSASR filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-catalent-inc-5818404)
- 2024-12-18 15:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-catalent-inc-5818402)
- 2024-12-18 15:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-catalent-inc-5818401)
- 2024-12-18 15:29 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-catalent-inc-5818396)
- 2024-12-18 14:49 UTC [SEC Form 8-K] [Catalent Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant](https://www.quantisnow.com/insight/catalent-inc-filed-sec-form-8-k-termination-of-a-material-5818364)
- 2024-12-18 14:24 UTC [SEC Form 25-NSE filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-catalent-inc-5818334)
- 2024-12-18 13:57 UTC [Novo Holdings Completes Acquisition of Catalent](https://www.quantisnow.com/insight/novo-holdings-completes-acquisition-of-catalent-5818245)
- 2024-12-16 11:08 UTC [SEC Form 8-K] [SEC Form 8-K filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-catalent-inc-5813892)
- 2024-12-14 05:06 UTC [Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction](https://www.quantisnow.com/insight/catalent-and-novo-holdings-fulfill-all-regulatory-closing-conditions-for-5813770)
- 2024-12-10 12:00 UTC [Leadership Update] [QuidelOrtho Announces Appointment of Two Independent Directors to its Board](https://www.quantisnow.com/insight/quidelortho-announces-appointment-of-two-independent-directors-to-its-board-5806597)
- 2024-12-06 18:26 UTC [SEC Form 8-K] [SEC Form 8-K filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-catalent-inc-5803373)
- 2024-12-06 18:08 UTC [Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction](https://www.quantisnow.com/insight/catalent-and-novo-holdings-receive-european-commission-unconditional-approval-for-5803361)
- 2024-11-14 21:35 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Catalent Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-catalent-inc-5776522)
- 2024-11-14 19:46 UTC [SEC Form 4] [Director Ryan Michelle R sold $167,160 worth of shares (2,800 units at $59.70), decreasing direct ownership by 21% to 10,835 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ryan-michelle-r-sold-167160-worth-of-shares-2800-5774995)
- 2024-11-14 14:50 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Catalent Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-catalent-inc-5773806)
- 2024-11-13 17:52 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Catalent Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-catalent-inc-5770772)
- 2024-11-05 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Catalent Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-catalent-inc-5753086)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CTLT
- Earnings history: https://www.quantisnow.com/earnings/CTLT
- Dividend history: https://www.quantisnow.com/dividends/CTLT
- Insider transactions: https://www.quantisnow.com/insiders/CTLT
- Options chain: https://www.quantisnow.com/options/CTLT
- SEC 8-K filings only: https://www.quantisnow.com/company/CTLT/8-k
- RSS and alerts for CTLT: https://www.quantisnow.com/docs/rss-feeds.md